Welcome Guest to Happi

Subscribe Free: Magazine | eNewsletter

current issue January 2015
 •  Former Coty Exec Named CEO at Illuminage Beauty  •  Cargo Works Sundance  •  Energizer’s Q1 Sales Drop  •  City of Hope To Honor Steve Goddard  •  Q2 ‘Challenging’ for P&G
Print

Valeant To Buy Bausch & Lomb



Published May 27, 2013
Related Searches: companies international growth industry
Post a comment
Valeant Pharmaceuticals International will pay $8.7 billion to acquire Bausch & Lomb, the eye care company. Under the terms of the deal, Valeant will pay $4.5 billion to the investor group that owns Bausch & Lomb, led by private equity firm Warburg Pincus. It will also spend about $4.2 billion to repay Bausch & Lomb’s debt.

 

The agreement continues the flurry of deal-making in the health care industry, as companies seek to buy the growth they are hard-pressed to generate on their own. Announced merger volume in the sector this year is up 14% from the period a year earlier, even as takeovers have fallen 8%.


This acquisition follows Valeant's April purchase for Obagi skin care for $348 million.

 



blog comments powered by Disqus